Rodman & Renshaw

Oasmia Pharmaceutical AB - American Depositary Shares (NASDAQ: OASM) enjoyed a healthy spike higher on volume Monday, perhaps due in part to an initiation of coverage from analysts at Rodman & Renshaw. Analyst Raghuram Selvaraju initiated Oasmia with a Buy rating and a $6 price target. With...

Rodman & Renshaw’s Heiko F. Ihle believes Hecla Mining Company (NYSE: HL)'s long-term focus, along with its portfolio of “long-lived” assets, would offer investors good exposure to any future upside in silver and gold prices. Ihle initiated coverage of the company with a Buy...

Rodman & Renshaw picked up Ring Energy Inc (NYSE: REI) in the energy exploration and production sector and initiated the company with a Buy rating on multiple catalysts. Analyst Noel Parks attached a price target of $15 based on risked net asset valuation of reserves. Best Suited In a tough oil...

Rodman & Renshaw initiated coverage on HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares with a Buy rating. The brokerage has a price objective of $5 on the company's stock, citing that the molecular profiling system required less sample material to deliver more. Analysts Raghuram Selvaraju...

Penny stocks typically don’t cost a penny anymore. Companies trading as high as $5 per share are now considered “penny stocks,” and for good reason. These stocks lack the stability and performance reliability of those with a bigger market cap. With that said, buying a fiver doesn...

Rodman & Renshaw initiated coverage on OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and $6.00 price target, describing the company as representing a unique opportunity in the oncology sector, positioned in the highly visible and widely-followed immunotherapy domain. Related Link:...

Rodman & Renshaw has started coverage of Orion Energy Systems, Inc. (NASDAQ: OESX) with a Buy rating and price target of $2.50, which implies an upside of 108 percent over Friday's close. Recent Performance Orion Energy makes energy efficient lighting systems, with a primary focus of expanding...

Rodman & Renshaw’s Raghuram Selvaraju mentioned that TearLab Corp (NASDAQ: TEAR)'s Osmolarity System for the diagnosis of dry eye disease (DED) is “the first and only objective DED diagnostic test in the U.S. that has FDA clearance and CLIA waiver.” Selvaraju initiated...

It’s not often that a Wall Street analyst will set a price target for a big-name stock that represents nearly 300 percent upside. But in a new research note, Rodman & Renshaw’s Raghuram Selvaraju did just that when he set a $90 price target for Valeant Pharmaceuticals Intl Inc (...

Rodman & Renshaw started coverage of Neurometrix Inc (NASDAQ: NURO) with a Buy rating and a target price of $4.50, implying an upside of 160 percent. NeuroMetrix is medical device company aimed at management of chronic intractable pain due to conditions such as diabetes, fibromyalgia and...

Rodman & Renshaw maintains its Buy rating and $12 price target on LabStyle Innovations Corp (NASDAQ: DRIO) after the company's better-than-expected first-quarter results. LabStyle Innovations reported lower-than-projected net loss of $0.33 per share versus the brokerage's estimate of $0.38 per...

Rodman & Renshaw maintains a Buy rating on Presbia PLC (NASDAQ: LENS) after an interim data from the company showed that its corneal inlay product, the Flexivue Microlens, can achieve "significant improvement in uncorrected near vision acuity without loss of distance vision performance." "An...

Rodman & Renshaw maintains its Buy rating on Just Energy Group Inc (NYSE: JE), saying that the stock is "undervalued" as the company is poised to benefit from its "strategy of allowing lower margin customer attrition." Why Buy? During the year ended March 31, 2016, the company lost about 166,...

Rodman & Renshaw's Raghuram Selvaraju reiterated his Buy position on Synergy Pharmaceuticals Inc (NASDAQ: SGYP) with a price target of $15.00. The rating reiteration comes after further Plecanatide Phase 3 data was reported, showing positive results. The new data "emphasizes what we view as the...

Rodman & Renshaw's Raghuram Selvaraju downgraded Nanosphere, Inc. (NASDAQ: NSPH) from Buy to Neutral, while decreasing the price target from $2.00 to $1.35. The rating change came after Luminex Corporation (NASDAQ: LMNX) announced it was acquiring Nanosphere for $1.35 a share in an all-cash...